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Abstract
Signal transducer and activator of transcription 3
(STAT3) is aberrantly activated in colorectal carcino-
mas (CRCs). Here, we define the relationship between
STAT3 function and the malignant properties of colon
carcinoma cells. Elevated activation of STAT3 en-
hances invasive growth of the CRC cell lines. To ad-
dress mechanisms through which STAT3 influences
invasiveness, the protease mRNA expression pattern
of CRC biopsies was analyzed and correlated with
the STAT3 activity status. These studies revealed a
striking coincidence of STAT3 activation and strong
expression of matrix metalloproteinases MMP-1, -3, -7,
and -9. Immunohistological examination of CRC tumor
specimens showed a clear colocalization of MMP-1 and
activated STAT3. Experimentally induced STAT3 ac-
tivity in CRC cell lines enhanced both the level of
MMP-1 mRNA and secreted MMP-1 enzymatic activity.
A direct connection of STAT3 activity and transcrip-
tion from the MMP-1 promoter was shown by reporter
gene experiments. Moreover, high-affinity binding
of STAT3 to STAT recognition elements in both the
MMP-1 and MMP-3 promoter was demonstrated. Xeno-
graft tumors arising from implantation of CRC cells
into nude mice showed simultaneous appearance and
colocalization of p-Y-STAT3 and MMP-1 expression.
Our results link aberrant activity of STAT3 in CRC
to malignant tumor progression through upregulated
expression of MMPs.
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Introduction
Carcinomas frequently show aberrant activity of signal
transducers and activators of transcription (STATs). In-
creased STAT3 activity is mostly tumor promoting, whereas
elevated STAT1 activity is tumor growth inhibiting [1]. Among
the members of the STAT family, STAT3 mediates the most
complex spectrum of cellular responses including differentia-
tion, proliferation, survival, and apoptosis, depending on the
tissue context [2]. Constitutive activity of STAT3 was observed
in many malignant tumors of both hematopoietic and solid type
[3]. In addition, an artificially dimerized variant of STAT3 was
shown to act as a bona fide oncoprotein by eliciting cellular
transformation of fibroblasts and tumorigenesis in nude mice
[4]. We have recently investigated biopsies of colorectal car-
cinomas (CRCs) and analyzed the spectrum of STAT activity.
Most significantly, we observed constitutive activation of
STAT3a in carcinoma cells of more than 90% of the tumors [5].
Experimental inhibition of STAT3 activity in tumor cell
lines and tumor tissue yielded promising results with regard to
STAT3 as an interesting target for tumor therapy [6–8]. Al-
though downstream events connecting aberrant STAT3 ac-
tivity to malignant cell properties are insufficiently defined,
they involve the upregulation of genes promoting cell cycle pro-
gression (cyclin D1, c-myc) and/or preventing apoptosis (bcl-x,
mcl-1, survivin) [4,9,10].
Recent studies showed that STAT3 activation in tumors may
be associated with metastasis and poor prognosis [8,11], indi-
cating that inappropriate signaling by STAT3 coincides with
invasive growth of cancer cells. Interestingly, blocking STAT3
activity reduced the motility of ovarian cancer cells whose
aggressive clinical behavior showed a correlation with consti-
tutively active STAT3 levels [12]. So far, how STAT3 promotes
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cancer development and whether it is able to control invasive
cell properties are largely undefined.
Tumor invasion and metastasis require proteolytic degra-
dation of the basement membrane and the extracellular
matrix (ECM). Matrix metalloproteinases (MMPs) are chiefly
involved in the dissemination of cancer cells by breaking
down the ECM and creating an environment that sup-
ports the initiation and maintenance of tumor growth. The
MMP family, consisting of roughly 20 members, displays a
conserved structure and enzymatic mechanism [13]. MMP
expression is low in most normal cells under regular physio-
logical conditions; however, it is dramatically increased in a
variety of cancer types, which is indicative of invasive disease
with a poor clinical prognosis [14–16]. Interestingly, knocking
out or inhibition of some MMPs results in the reduction of
tumor growth. For instance, the spontaneous development of
intestinal tumors in mice with adenomatous polyposis coli
(Apc) gene mutations is slower in MMP-7–deficient animals
[17]. Moreover, experimental metastasis is suppressed in
MMP-9–deficient mice [18], and MMP-11 knockout mice
show reduced chemically induced tumorigenesis [19]. In-
hibitors acting on MMP-1, MMP-3, MMP-7, and MMP-9 be-
haved as potent antiangiogenic and antimetastatic agents
in animal models [20,21].
The recognition of STAT proteins as being potential
players in oncogenic cell transformation was paralleled by
their involvement in the modulation of activity for both
promoters of MMPs and tissue inhibitors of MMP (TIMPs)
[22–26]. A recent report demonstrated that transcriptional
upregulation of MMP-9 is directly involved in the oncogenic
transformation of mammary epithelial cells via a constitu-
tively active mutant of STAT3 [27]. Similar studies on other
MMPs have not yet been published.
The interstitial collagenase MMP-1 degrades collagen
types I, II, and III, which are the most abundant proteins of
the ECM [28]. It is already well established that MMP-1 is
required for invasive growth of tumor cells [29]. For instance,
it plays a critical role in the development of malignancy in
CRC. Levels of MMP-1 increase during CRC progression
and higher levels of expression are associated with shorter
disease-free survival times [30,31]. The particular importance
of MMP-1 for increased invasiveness of colon carcinoma
cells in vitro has recently been demonstrated [32].
Various stimuli such as cytokines, growth factors, cell–
cell, and cell–matrix interactions influence MMP expression
through transcriptional regulation [33]. Well-characterized
intracellular signal transduction reactions leading to the
modulation of MMP promoter activity are mostly centered
around mitogen-activated protein kinases, which, upon acti-
vation, enter the nucleus and phosphorylate transcription
factors such as AP-1 and Ets proteins [34,35]. The complex
transcriptional regulation of MMP promoters also involves
contributions from more specific transcription factors, in-
cluding NFnB as a mediator of toll-like receptors [36] and
Smads, which are effectors of receptors for transforming
growth factor-b, activins, and related ligands [37].
Our finding that STAT3 is activated in most CRCs left
us with the question as to how STAT3-driven transcription
might contribute to the malignancy of CRC cells. Reports on
the involvement of janus kinase (JAK)/STAT signaling in
the regulation of invasion-associated proteases [23–25]
prompted us to study the correlation of STAT3 activation
and MMP protease expression in CRC. Here, we show for
the first time a causal role of STAT3 for the elevated expres-
sion of MMP-1, MMP-3, MMP-7, and MMP-9 in CRC leading
to increased invasiveness of tumor cells.
Materials and Methods
Tumor Biopsies
Surgical tumor specimens were obtained from patients
with CRC after approval of the study by the local ethical
committee. Biopsies were snap-frozen in liquid nitrogen
immediately after resection. For protein and RNA analysis,
frozen blocks were disintegrated mechanically by using a
Micro Dismembranator (Braun, Melsungen, Germany). For
Western blot studies, whole-cell extracts were prepared
by suspending the material in a buffer containing 20 mmol/
l Hepes (pH 7.9), 400 mmol/l NaCl, 1 mmol/l EDTA, 20%
glycerol, 1 mmol/l dithiothreitol, 1 mmol/l phenylmethyl-
sulfonyl fluoride, 5 mg/ml leupeptin, 0.2 U/ml aprotinin,
5 mmol/l sodium orthovanadate, 10 mmol/l NaF, and 5 mol/l
b-glycerophosphate, followed by three to four freeze–thaw
cycles in liquid nitrogen and on ice. Extracts were cleared
at 20,000g for 30 minutes at 4jC. Supernatants were sub-
jected to protein determination and SDS-PAGE. Total RNA
was isolated from disintegrated biopsies by homogeniza-
tion in TRIzol Reagent (Gibco BRL, Gaithersburg, MD) as
described below.
Cell Lines and Cell Culture
Colon carcinoma cell line HT-29 was purchased from
the American Type Culture Collection (Rockville, MD). Low
passage number cell line CoGa-1 [38] was obtained from
L.A. Huber, Innsbruck. All cell lines were cultured in RPMI
1640 medium containing 10% fetal calf serum, 200 mmol/l
L-glutamine, 100 mmol/l sodium pyruvate, and 1 mg/ml
gentamycin. Cells were grown in coated tissue culture plas-
ticware (Greiner Labortechnik, Frickenhausen, Germany).
For cytokine stimulation, HT-29 or CoGa-1 cells were
incubated with 20 ng/ml recombinant human interleukin
(IL)-6 (R&D Systems GmbH, Wiesbaden, Germany) for
30 minutes (Western blotting), 18 hours (reporter gene
assay) or 24 hours (expression analysis) at 37jC. Cells
were harvested at 80% confluence after three PBS washes
at 4jC. Whole-cell extracts were prepared from cell pellets
as described above.
DNA Constructs
Construction of the retroviral expression plasmids for
STAT3 mutants and generation of HT-29–derived cell lines
by retrovirus infection has been described previously [5].
CoGa-1 clones stably expressing STAT3 wild type or the
constitutively active STAT3 mutant (STAT3 c.a.) were gen-
erated similarly.
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The MMP-1 promoter/luciferase reporter plasmid 4372
hMMP-luci (GenBank accession no. AF023338), obtained
fromC. E. Brinckerhoff (DartmouthMedical School, Hanover,
NH) was described previously [39].
Electrophoretic Mobility Shift Assay
Extracts from tumor biopsies and cultivated cells were
prepared and subjected to band shift analysis as described
[5]. Briefly, double-stranded, blunt-ended oligonucleotides
corresponding to known and potential STAT binding sites
were annealed and end-labeled using [32P]g-ATP and T4
polynucleotide kinase to a specific activity of 10,000 cpm/fmol
as described [40,41]. Binding reactions were performed by
incubating 10,000 cpmof radiolabeled probewith 20 mg of cell
lysate for 30 minutes at room temperature. For supershift
reactions of STAT3-containing complexes, 2 mg of anti-STAT3
antibody C-20 (Santa Cruz Biotechnology, Santa Cruz, CA)
was added to the binding reactions. Samples were sepa-
rated by electrophoresis through 6% native polyacrylamide
gels and analyzed by autoradiography using BioMax sensi-
tive films (Kodak, Stuttgart, Germany). For the determination
of inducible STAT3 binding to potential binding sites, 293T
cells were cotransfected with eukaryotic expression vectors
for STAT3 and JAK2 by the lipofectamine transfectionmethod
and further treated as described [40,41]. Cells were optionally
stimulated with human IL-6 (10 ng/ml; R&D Systems) for
30 minutes before harvesting. Extracts were prepared
using unstimulated [plain DMEM containing 10% fetal calf
serum (FCS)] versus IL-6–stimulated extracts. The mutated
‘‘m67’’ STAT-binding site from the human c-fos promoter 5V-
GTCGACATTTCCCGTAAATCGTCGA-3V [41] served as a
positive control for high-affinity binding of STAT3.
Immunohistology
Immunohistological detection of MMP-1 expression in
tumor biopsies was performed as described previously [42].
Briefly, formalin-fixed, paraffin-embedded sections (4 mm)
were deparaffinized and subsequently treated with 0.3%
H2O2 for 30 minutes to reduce endogenous peroxidase
activity. Sections were incubated at 4jC overnight with a
1:50 dilution of anti–MMP-1 (Dako Diagnostik, Hamburg,
Germany) in TBS buffer containing 20% goat serum to block
unspecific binding sites, followed by incubation with goat
anti-mouse biotin and streptavidin–horseradish peroxidase
(BioGenex, San Ramon, CA) and development with di-
aminobenzidine. Finally, all specimens were coverslipped
using Aquatex (Merck, Darmstadt, Germany). Negative con-
trols were performed by omission of the primary antibody.
Soft Agar Assay for Anchorage-Independent Growth
Formation of colonies in soft agar as a parameter of cell
transformation was determined as described [43]. Briefly,
HT-29– or CoGa-1–derived cells were assayed by seeding
10,000 cells into 500 ml of 0.6% agar (Agarose nobile, Becton
Dickinson, Bedford, MA) diluted in RPMI 1640 medium con-
taining 10%FCS. Themixture was poured into six-well plates
lined previously with 500 ml of 0.5% agar in medium. The
plates were incubated for 2 to 3weeks at 37jC; 250 ml of fresh
medium was added every 3 days. After this period, colonies
were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT, 500 mg/ml) at 37jC for 2 hours
before photography and counting.
In Vitro Cell Invasion Assay
Cell invasiveness was quantified by a modified Boyden
chamber method using polycarbonate transwells (Corning
Costar Corp., Cambridge, MA) as described in detail pre-
viously [44]. Briefly, 2  105 exponentially growing cells
were seeded onto membrane filters coated with Matrigel
(Becton Dickinson) and transmigration through the Matrigel
layer was monitored after incubation for 24 hours at 37jC.
The percentage of invasive cells was expressed by relating
the total number of migrated cells to the number of cells
originally applied to the top of the transwell, which was set
at 100%.
Protease Expression Analysis by cDNA Arrays
cDNAmacroarrays on the basis of nylonmembraneswere
prepared as described previously [44]. Information on the
sequences and the arrangement of probes as well as ex-
perimental details are available upon request.
Polymerase chain reaction (PCR) primers used to generate
the probes relevant in this study were the following: MMP1
sense, 5V-AGGGTCAAGCAGACATCATG-3V; MMP1 anti-
sense, 5V-AGCATCGATATGCTTCACAGT-3V; MMP3 sense,
5V-TTGCAGTTAGTGAACATGGA-3V; MMP3 antisense, 5V-
ATCCAGCTCGTACCTCA-3V; MMP7 sense, 5V-GGCATGA-
GTGAGCTACAGTG-3V; MMP7 antisense, 5V-CCAGC-
GTTCATCCTCATCGA-3V; MMP9 sense, 5V-CTTCTACGGC-
CACTACTGTG-3V; MMP9antisense, 5V-CACTGCAGGATGT-
CATAGGT-3V; b-actin sense, 5V-ACCACGGCCGAGCGG-
GAAATC-3V; and b-actin antisense, 5V-GAGCCGCCGATCC-
ACACGGAGTA-3V.
Hybridization pattern data were processed by use of the
AIDA imaging software (Raytest, Straubenhardt, Germany).
The average densitometry signals of the duplicate spots,
minus background, were calculated. The signals were then
normalized against an average of all signals from the re-
spective membranes and expressed as relative densito-
metric units.
Quantification of Specific mRNAs by Real-Time PCR
Quantitation of cDNA from specific mRNA transcripts was
accomplished by real-time reverse transcription-PCR
(RT-PCR) using the TaqMan protocol and an ABI/Prism
7000 equipment (Applied Biosystems, Foster City, CA). Pre-
designed fluorogenic Assays-on-Demand TaqMan probes
and primer pairs for MMP-1 (Hs00233958_m1) and 18S
rRNA (Hs99999901_s1) were obtained from Applied Bio-
systems. The following 6-carboxy-fluorescein– labeled
probes were used for PCR amplification: MMP-1, 5V-AAAGA-
CAGATTCTACATGCGCACAA-3V; 18S rRNA, 5V-TGGAG-
GGCAAGTCTGGTGCCAGCAG-3V. The specific primers
for MMP-1 and 18S rRNA were predicted to amplify 150-
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and 120-bp DNA fragments, respectively. A total reaction
volume of 25 ml contained 12.5 ml of 2  TaqMan Universal
Master Mix, No AmpErase UNG (Applied Biosystems),
3 ml cDNA (prepared as described above), 1.25 ml of 20 
Assays-on-Demand Gene Expression products (Applied
Biosystems) for MMP-1, consisting of 20  mix of unlabeled
PCR primers (18 mmol/l) and 5 mmol/l TaqMan MGB probe
(6-carboxy-fluorescein dye– labeled MMP-1). Forty PCR
cycles of 95jC for 15 seconds and 60jC for 1 minute were
run after an initial incubation at 95jC for 10 minutes.
The MMP-1 gene copy number in samples to be analyzed
was quantified by simultaneously generating a standard
curve for both MMP-1 and 18S rRNA as an endogenous con-
trol from serial dilutions of HT-29 cDNA (equivalent to a cDNA
amount from 100 ng to 100 pg of initial total RNA). The target
amounts of unknown samples were divided by the endoge-
nous reference amount to obtain a normalized target value.
Resultswere expressed asn-fold differences inMMP-1mRNA
relative to 18S rRNA. Data collection and analysis was
performed with the SDS software version 1.0.1 (Applied
Biosystems). Data were then exported and further processed
using the Excel software (Microsoft, Redmond, WA).
Luciferase Reporter Gene Assay
Exponentially growing cells (7  105) of HT-29 and
CoGa-1 derivatives were plated in six-well cluster plates
(Greiner) in 2 ml RPMI 1640/10% FCS and grown to 80%
to 90% confluency. The cells were washed, transferred into
1ml/well freshmedium, and cotransfected with 1 mg of MMP-1
promoter/luciferase construct and 0.1 mg of the pRL-TK
Renilla luciferase plasmid (Promega, Madison, WI) as an
internal control for transfection efficiency by using PolyFect
reagent (Qiagen, Hilden, Germany). Both DNAs were diluted
with growth medium containing no serum, antibiotics, or
proteins to a final volume of 100 ml. The solutions were mixed
and 9 ml of PolyFect was added per well. The mixture was
incubated at room temperature for 5 to 10 minutes to allow
complex formation before 1 ml medium was added. After
14 hours incubation at 37jC, the cells were gently washed
with RPMI 1640 and incubated with fresh RPMI, optionally
containing IL-6 (20 ng/ml). The cells were harvested 8 hours
later using reporter lysis buffer (Promega). Luciferase and
Renilla activities were determined with the Dual-Luciferase
Reporter Assay System kit from Promega and following the
manufacturer’s instructions. Luminescence was measured
on a Micro Luminat LB 96 P Luminometer and reported as
relative light units. Three independent transfections, each
run in triplicate, were performed, and the results were nor-
malized to the Renilla activity.
Determination of MMP-1 Activity in Cell Supernatants
Levels of enzymatically active MMP-1 were measured
using an MMP-1 Fluorokine E ELISA kit (R&D Systems)
according to the manufacturer’s instructions. HT-29–derived
cells were cultivated for 4 days in RPMI 1640/10% FCS in the
presence or absence of 20 ng/ml IL-6. After centrifugation
(4jC, 1000g, 5 minutes), 150 ml of culture supernatants
from HT-29 cells was mixed with 100 ml of Assay diluent
buffer (R&D Systems) in individual wells of 96-well ELISA
plates. Simultaneously, standard samples containing known
concentrations of active MMP-1 were treated in the same
fashion. The plates were gently shaken for 3 hours at room
temperature before unbound material was washed off. Sub-
sequently, 200 ml of activation reagent (0.5 M APMA in
DMSO, R&D systems) was added to each well for pro–
MMP-1 activation. The plates were incubated for 2 hours
at 37jC in a humidified environment. After washing, 200 ml
of 1 mmol/l fluorogenic substrate in DMSO (R&D Systems)
was added. After another 20 hours at 37jC, fluorescence
was determined using a fluorescence plate reader set
(SPECTROmax plus, Molecular Devices, Sunnyvale, CA)
with an excitation wavelength set to 320 nm and emission
wavelength set to 405 nm. Standard curves were gen-
erated by plotting the mean relative fluorescence units for
each standard for active MMP-1 against the concentrations.
Concentrations of active MMP-1 in the cell supernatant
samples were determined from the standard curves.
Xenograft Experiments
A total of 105 cells of the HT-29 cell line was suspended in
PBS and injected subcutaneously at a volume of 100 ml into
the neck of 5- to 8-week-old male athymic Hsd:NMRI-nu/nu
mice (Harlan, Indianapolis, IN). Mice were sacrificed after the
tumors had reached a size of approximately 2000 mm2.
Tumor specimens were further treated similarly to the human
biopsy samples (see above).
Statistical Analysis
Statistical analysis was performed using SPSS software
version 11.0 (SPSS, Chicago, IL). To calculate significance
levels, data sets were compared using the Wilcoxon test
for paired samples and Mann–Whitney test for unpaired
samples, respectively. Probability values of P < .05 were used
as the generally accepted level of statistical significance.
Results
STAT3 Activity Enhances Anchorage-Independent Growth
and Invasiveness of CRC Cells
We have shown that STAT3 is constitutively active in
carcinoma cells from a majority of human CRC biopsies. It
also drives proliferation of both the established CRC cell line
HT-29 and the low passage number colon cancer cell line
CoGa-1 [5]. To address the role of STAT3 in the develop-
ment and maintenance of malignancy, we studied the in-
fluence of STAT3 activity on parameters of cell transformation
in both cell lines.
First, the STAT3 expression–dependent formation of
colonies in soft agar was determined as a measure of onco-
genic cell transformation. For this purpose, we employed
nontransfected HT-29 and CoGa-1 cells as well as deriva-
tives stably overexpressing STAT3 or the mutant STAT3 c.a.,
respectively. STAT3 c.a. functions independently of cytokine
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activation through dimerization via an artificial disulfide
bridge. After confirmation of elevated STAT3 DNA-binding ac-
tivity in the transfected cells compared with the parental cell
lines [5] (data not shown) cells were seeded into soft agar,
overlaid with medium, and incubated for 2 weeks before
colonies were counted. As shown in Figure 1, in both cell lines
an overexpression of wild type or, to a higher degree, of
STAT3 c.a., resulted in a profoundly increased number of colo-
nies, most notably in the absence of exogenous cytokines.
Next, we addressed the influence of STAT3 on the inva-
sive cell properties of colon carcinoma cells as measured by
their ability to cross an artificial ECM (Matrigel). Parental cells
of HT-29 and CoGa-1 as well as derivatives overexpressing
either STAT3 or STAT3 c.a. were seeded onto a layer of
Matrigel and analyzed after 24 hours for the fraction of cells
migrating through the gel and accumulating in the lower
compartment of a transwell chamber (Figure 1C). In both
cases, cells expressing STAT3 c.a. and overexpressing
STAT3 had a much stronger invasive character than the
parental CRC cell lines, indicating that STAT3 has an en-
hancing effect on invasiveness in colon carcinoma cells.
To support this notion, we measured the invasiveness
of HT-29 cells dependent on STAT3 activation through IL-6
and/or reduction of STAT3 activity by means of a dominant-
negative STAT3mutant (STAT3 d.n.). As shown in Figure 1D,
IL-6 evoked stronger cell invasiveness of HT-29 cells in
addition to enhancing the invasion-promoting effect of over-
expressed STAT3. On the other hand, expression of STAT3
d.n. with the critical Tyr705 mutated to Phe, which blocked
receptor-mediated activation of endogenousSTAT3, reduced
the constitutive invasiveness of HT-29 cells and completely
suppressed the effect of IL-6. These results are in good
accordance with the tyrosine phosphorylation status of
STAT3 in HT-29 cells under the respective conditions [5]
and indicate a clear correlation of STAT3 activity with the po-
tency of cells to grow in an invasive manner.
Elevated Expression of MMPs in Colorectal Tumor Biopsies
Coincides with Constitutive Activity of STAT3
Our results initiated the question of the mode of action
of STAT3 in enhancing the invasiveness of colon carci-
noma cells. Proteinases, in particular collagenases, are
known to be key lytic enzymes required for the invasion
process because their inhibition totally prevented amnion
or Matrigel invasion [45]. To explore the molecular mecha-
nisms responsible for STAT3-mediated tumor invasion, we
Figure 1. Influence of STAT3 expression and activity on soft agar colony formation and invasiveness of colon carcinoma cells. (A and B) Dependence of colony
formation of HT-29 and CoGa-1 cells on STAT3 expression and activity. Cell lines overexpressing STAT3 or STAT3 c.a. as well as nontransfected control cells were
grown in soft agar for 2 weeks. Colonies formed were visualized by staining with MTT (500 g/ml) (bottom) and counted (top). The values represent triplicate
experiments. (C) STAT3 expression– and activity-dependent invasiveness in vitro of HT-29–derived cell lines. HT-29, HT-29-STAT3, and HT-29-STAT3 c.a. cells
were incubated in invasion chambers containingMatrigel-coatedmembranes. After 24 hours, cells that hadmigrated through bothMatrigel andmembrane to the lower
compartment of the system were counted. Invasiveness was expressed as the percentage of cells that had reached the lower chamber at the end of the experiment.
The assay was repeated four times in triplicate. (D) IL-6– induced invasiveness of HT-29 cells and derivatives. HT-29, HT-29-STAT3, and HT-29-STAT3 d.n. were
grown on Matrigel-coated membranes as in (C). IL-6 was optionally present in the medium (+; striped columns) at a concentration of 20 ng/ml 24 hours before the cell
lines were tested and throughout the entire experiment. The experiment was repeated three times. All treatments were performed in triplicate.
STAT3 Drives Invasiveness through MMP Induction in Colon Cancer Tsareva et al. 283
Neoplasia . Vol. 9, No. 4, 2007
correlated STAT3 activation in colorectal tumors with pro-
tease expression.
First, we verified the previously determined status of
32 CRC biopsies with regard to STAT3 tyrosine phosphory-
lation [5] by electrophoretic mobility shift assay (EMSA)
analysis of specific DNA-binding activity (data not shown)
and categorized them into a ‘‘high STAT3’’ and a ‘‘low
STAT3’’ group. A total of 13 samples with strikingly strong
STAT3 activity in both assays were considered high STAT3,
and 9 biopsy samples with very low STAT3 activity were
considered low STAT3. Figure 2A shows five representa-
tive examples from each group. Seven samples with inter-
mediate activity and three samples completely negative for
STAT3 activity were excluded from further analysis. The
remaining samples were tested in a comparative fashion
for the respective abundance of protease mRNAs by sub-
jecting them to the isolation of total RNA and the synthesis
of digoxigenin-labeled cDNAs. cDNAs were hybridized to
arrays covering 50 different human protease probes (ar-
rangement of probes on the arrays is available upon re-
quest). Figure 2B shows in one representative biopsy for
each group that in particular the mRNAs for MMP-1, MMP-
3, MMP-7, and MMP-9 were much more abundant in colo-
rectal tumor tissue with a high degree of STAT3 activity.
Figure 2C summarizes expression data for the MMPs
obtained from a larger population of tumors (22 patients in
total) quantitated by densitometric determination of signal
intensities of the arrays. MMP-1 was given special attention
because its expression appeared to correlate with STAT3
activity in a particularly evident fashion and because of its
important role in the invasiveness of colon carcinoma cells.
As an independent criterion for MMP-1 expression, we de-
termined MMP-1 mRNA in 13 specimens of high STAT3
and 9 specimens of low STAT3 colorectal tumor biopsies by
real-time PCR. Figure 2D shows that the expression of
MMP-1 was strikingly higher in tumors of strong STAT3
activity, confirming the results previously determined by
using cDNA arrays.
MMP-1 Expression in CRC Is Colocalized with
STAT3 Activity
Previously, we have shown that phosphorylated STAT3 in
colorectal tumor tissue is predominantly localized to de-
differentiated epithelial cells [5]. To further elucidate possible
functional connections between persistent STAT3 activity
and elevated MMP expression, we studied the spatial distri-
bution of MMP-1 expression in CRC tissue using immuno-
histochemical methods. Sections from biopsies, classified
high or low STAT3 according to both biochemical and histo-
logical testing, were stained with an antibody to MMP-1.
Figure 3 shows that no significant MMP-1 expression was
detected in and around normal crypts of both high- and low-
STAT3 specimens. In contrast, the two tumor types showed a
strikingly diverse picture with regard to MMP-1 abundance in
Figure 2. Correlation of STAT3 activation and protease expression in CRC biopsies. (A) EMSA analysis of STAT3 activation in CRC biopsies scored as low STAT3
or high STAT3 according to previous determination of STAT3 tyrosine phosphorylation [5]. Extracts were incubated with the double-stranded 32P-labelled SIE m67
STAT binding site. Complexes were resolved on 6% native polyacrylamide gels and visualized by autoradiography. The identity of STAT3-containing complexes was
verified by including an antibody to STAT3 in the binding reactions as indicated. Positions of the specific STAT3-containing complexes are marked by arrows. (B)
Comparative analysis of protease expression in a respective CRC sample with high and low STAT3 activity using protease cDNA macroarrays. Total RNA isolated
from tumor samples was reverse transcribed into digoxigenin-labeled cDNA samples, which were hybridized to cDNA arrays covering probes for 50 different
human proteases. (C) The relative expression levels of MMP-1, -3, -7, and -9 in 5 tumor samples of each group determined as in (B) were quantified by densitometry
and normalized to four ‘‘housekeeping’’ mRNAs (GAPDH, -actin, ubiquitin, and R-13a). (D) Quantification of MMP-1 mRNA expression levels in CRC biopsies of
the high-STAT3 and low-STAT3 type. Three independent experiments, each run in triplicate, were performed; results were normalized to 18S rRNA expression
and expressed as the means ± S.D. Relative MMP-1 expression was calculated by arbitrarily setting the expression level of high-STAT3 samples as 1.
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tumor tissue. Whereas tumor cells in the STAT3 low sample
were virtually negative for MMP-1 expression, tumorous
epithelium in the high-STAT3 specimens displayed strong
MMP-1 staining. There was no significant MMP-1 expression
in stromal cells (i.e., fibroblasts, inflammatory cells) around
the cancerous tissue.
These findings indicate that an abundance of MMP-1
mRNA in CRC specimens of the high-STAT3 type results in
considerable levels of immunoreactive MMP-1 protein within
the malignant areas of the tumors.
STAT3 Drives Expression of Active MMP-1 in CRC Cells
To investigate a possible causal link between STAT3
activity and expression of MMP-1 in colon carcinoma cells,
we examined MMP-1 gene transcription upon experimental
activation of STAT3 in the HT-29 colon carcinoma cell line.
Previously, we have shown that although quiescent HT-29
cells are negative for STAT3 activity, STAT3 is activated by
IL-6. In addition, we generated HT-29 derivatives that either
overexpress STAT3 (HT-29 STAT3) or stably express a con-
stitutively active (HT-29 STAT3 c.a.) or a dominant-negative
STAT3 variant (HT-29 STAT3 d.n.), respectively [5].
STAT3 activity in HT-29 cells was manipulated via IL-6
stimulation or through protein expression of the variants, and
the resulting changes in both MMP-1 mRNA and MMP-1
enzyme activity were determined (Figure 5). MMP-1 mRNA
was quantified by real-time PCR, whereas MMP-1 activity
was measured by the turnover of a fluorogenic substrate.
Figure 4A shows that incubating HT-29 cells with 20 ng/ml
IL-6 leads to a clear increase in MMP-1 mRNA. An over-
expression of STAT3 in HT-29 STAT3 cells, which coincides
with a threshold activity of STAT3 tyrosine phosphorylation
[5], results in an increase of MMP-1 mRNA compared with
parental HT-29 cells. IL-6 stimulation of HT-29 STAT3 cells
evokes a further strong increase in the concentration of
MMP-1 mRNA. A stable expression of the constitutively
active STAT3 variant in HT-29 STAT3 c.a. cells resulted in a
more than threefold increase of MMP-1 mRNA compared
with nontransfected cells.
The analysis of MMP-1 enzyme activity in HT-29 cells
under an experimentally altered status of STAT3 activation
gave similar results (Figure 4B). Stable expression of STAT3
as well as acute IL-6 stimulation evoked a more than 10-fold
induction of MMP-1 enzyme activity in HT-29 cells. Stimula-
tion of both HT-29 cells and HT-29 STAT3 cells led to
enhanced MMP-1 activity compared with nonstimulated
cells. Notably, the expression of a dominant-negative STAT3
variant (STAT3 Y705F) completely suppressed both basal
and IL-6–induced MMP-1 activity in HT-29 cells.
These results clearly suggest that STAT3 is essential for
increased expression of MMP-1 in CRC. More importantly,
tyrosine phosphorylation analysis shows that the respective
degrees of MMP-1 induction in HT-29 observed under varied
conditionsmirror the respective levels of STAT3activation [5].
Figure 3. Immunohistochemical staining for MMP-1 in paraffin-embedded specimens of high-STAT3 and low-STAT3 primary CRC biopsies. Sections from
representative tumor samples positive (top) and negative (bottom) for tyrosine-phosphorylated STAT3, showing both differentiated normal cells in crypt structures
and de-differentiated tumor tissue, were treated with an antibody specific for MMP-1. Sites of differentiated normal cells in crypt regions, of tumor tissue, and of
stromal cells are indicated by arrows in the left-hand pictures, center, and right-hand pictures show enlargements of tumor tissue and normal crypt structures.
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To determine whether activated STAT3 enhanced tran-
scription from the MMP-1 promoter in colon carcinoma cells,
we employed the reporter gene construct 4372 hMMP-luci
in which the 4.3-kb human MMP-1 promoter was placed
upstream of a luciferase reporter gene [39]. First, the reporter
gene construct was transiently transfected into parental
HT-29 cells and into HT-29 derivatives stably (over) ex-
pressing either STAT3 or STAT3 c.a. (Figure 4C). We ob-
served that enhanced STAT3 expression and activity in
both cell lines resulted in a two- to threefold increase in
transcription driven by the MMP-1 promoter compared with
nontransfected cells.
Figure 4D shows that IL-6 treatment strongly induced the
activity of the MMP-1 promoter in HT-29 cells as well as in
HT-29 cells overexpressing STAT3. In HT-29 STAT3 c.a.
cells, IL-6 did not induce a further increase ofMMP-1 transcrip-
tion compared with nonstimulated cells (data not shown),
probably due to a saturation of the respective mechanisms.
These data demonstrate that STAT3 activation promotes
transcriptional activity of the MMP-1 promoter in HT-29 cells.
They also point to a functional relation between STAT3
activity and expression of a proteasewith particular relevance
for tumor cell malignancy by tissue invasion.
Xenografts of HT-29 Cells Develop STAT3 Activity
and MMP-1 Expression Simultaneously and in a
Colocalized Fashion
We have previously shown that HT-29 cells are negative
for tyrosine-phosphorylated STAT3 activity in cell culture but
develop STAT3 activity when growing out into tumors in nude
mice [5]. Here, we demonstrated a transcriptional connection
between STAT3 activation and induction of MMP-1 expres-
sion in colon carcinoma cells. We wanted to further substan-
tiate these results by demonstrating that the development of
STAT3 activation in HT-29 xenograft tumors is accompanied
by an increase in MMP-1 abundance. First, by quantitative
RT-PCR, we compared the levels of MMP-1 mRNA in cul-
tured HT-29 cells with those in xenograft tumors arising
2 weeks after injection into nude mice. Figure 5A shows that
the relative quantity of MMP-1 mRNA in HT-29–derived
tumors was over fivefold higher compared with HT-29 cells
cultivated in vitro.
Next, we studied the effect of altered STAT3 activity in
HT-29 cells on MMP-1 expression upon development of
xenograft tumors. Tumors grown from HT-29 cells as well as
from HT-29 derivatives expressing constitutively active STAT3
(HT-29 STAT3 c.a.) or dominant-negative STAT3 Y705F
Figure 4. Determination of MMP-1 expression in HT-29 colon carcinoma cells dependent on STAT3 activation. (A) Influence of STAT3 activation by cell stimulation
with IL-6 and/or (over)expression of STAT3 variants. Parental HT-29 cells and derivatives stably expressing STAT3 or STAT3 c.a. were grown for 24 hours in the
absence or presence of 20 ng/ml IL-6 as indicated. Total RNA was isolated, transcribed into cDNA, and subjected to quantitative RT-PCR with specific primers and
probes for MMP-1 as described in Materials and Methods. Three independent experiments, each run in triplicate, were performed, and the results were normalized
to 18S rRNA expression. Relative MMP-1 expression was calculated by arbitrarily setting the expressions from samples with STAT3 c.a. as 1 (100%). (B) Influence
of STAT3 activation on enzymatic MMP-1 activity. HT-29 cells (over)expressing STAT3, the constitutively active variant STAT3 c.a. or the dominant-negative
STAT3 mutant Y705F (STAT3 d.n.) were cultured for 4 days in the absence or presence of 20 ng/ml IL-6 as indicated. Culture supernatants were assayed for
active MMP-1 by the turnover of a fluorogenic substrate as described in Materials and Methods. Data represent the means of three independent experiments. (C)
Influence of STAT3 expression in HT-29 cells on MMP-1 promoter activity. HT-29 cells or HT-29 cells stably (over)expressing STAT3 or STAT3 c.a., respectively,
were transiently transfected with 1 g of the 4372 hMMP-luci plasmid together with 0.1 g of Renilla plasmid as an internal control. After 14 hours, cells were
harvested and protein lysates were assayed for luciferase and renilla luciferase activities as described in Materials and Methods. (D) Influence of IL-6– induced
STAT3 activation on MMP-1 promoter activity in HT-29 cells. The experiment was performed as described in (C), but after 14 hours cells were washed and, before
lysis, incubated for 8 hours with fresh medium with or without 20 ng/ml IL-6 as indicated. Results in (C) and (D) represent the means of three independent
transfections, each run in triplicate.
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(HT-29 STAT3 d.n.) were subjected to immunohistochemical
examination using antibodies to tyrosine-phosphorylated
STAT3 and MMP-1 (Figure 5B). Both antibodies stained
carcinoma cells in HT-29 tumors, and costaining with both
antibodies revealed a colocalization of the two antigens.
Levels of both p-Y-STAT3 and MMP-1 were clearly enhanced
in tumors derived from HT-29 STAT3 c.a. cells and hugely
diminished in tumors of HT-29 STAT3 d.n. cells.
These data further support our notion that STAT3 activa-
tion is directly involved in the control of expression and activity
of MMP-1, and, thus, malignancy, of colon carcinoma cells.
High-Affinity Binding Sites for STAT Transcription Factors
Exist within the Promoters for Human MMP-1 and MMP-3
Finally, we wished to demonstrate that STAT3 directly
interacts with human MMP promoters and to identify relevant
binding sites. To this end, the sequences of the human
promoters for MMP-1 and MMP-3 were analyzed for DNA
elements matching the known STAT-binding consensus se-
quence as given by Ehret et al. [46]. Using the MEME search
blast algorithm [47], we identified six potential high-affinity
STAT3 binding within the human MMP-1 promoter (GenBank
accession no. AF023338) and four within the human MMP-3
promoter (GenBank accession no. U43511) and ordered
them within the respective groups by decreasing similarity
with the consensus STAT3 binding site defined by Ehret
et al. (Figure 6A).
Oligonucleotide hybrids representing these sequences
and a wild-type and a mutant (m67) STAT3-binding site from
the human c-fos promoter [41] as positive controls were
subjected to EMSA analysis for specific binding of activated
STAT3. Upon expression in 293T cells, STAT3 was acti-
vated by IL-6 stimulation. Appearance of STAT3–DNA com-
plexes was tested and verified by supershifting. As shown in
Figure 6B, one site from each MMP-1 and MMP-3 promoter,
notably the ones with the highest similarity to the consensus
according to the MEME search blast, specifically interacted
Figure 5. Determination of MMP-1 expression in HT-29 xenograft tumors in
correlation with STAT3 activity. (A) Comparative quantification of MMP-1
mRNA in cultured HT-29 cells and HT-29–derived xenograft tumors. Total
RNA was isolated from confluent cultures of HT-29 cells or from a rep-
resentative xenograft tumor explanted 2 weeks after subcutaneous injection
of cells into a nude mouse. RNA was transcribed into cDNA, and quantitative
RT-PCR with specific primers and probes for MMP-1 was performed as
described in Materials and Methods. Results were normalized to 18S rRNA
expression. Relative MMP-1 abundance was expressed as fraction of the
value for the xenograft tumor, which was arbitrarily set 1. The figure repre-
sents the means of three independent experiments. (B) Immunohistochemical
examination of HT-29–derived xenograft tumors for activated STAT3 and
MMP-1. Representative sections from a tumor induced by injection of HT-29
(top), HT-29 STAT3 c.a. (center), and HT-29 STAT3 d.n. (bottom) into nude
mice were reacted with an antibody specific for MMP-1 (left) or STAT3 pY705
(center) or with a combination of both antibodies (right).
Figure 6. Specific binding of STAT3 to cognate sequence elements within
the human MMP-1 and MMP-3 promoters. (A) Sequences of potential STAT
binding sites in the human MMP-1 and MMP-3 promoter as well as known
STAT3 recognition elements employed as controls. Sites were identified using
the MEME search blast algorithm [47] and ordered by decreasing similarity
with the consensus STAT3 binding site defined by Ehret et al. [46]. Positions
relative to the respective transcriptional start sites are given in brackets. (B)
Analysis of STAT3 DNA binding to four potential STAT binding elements
from the human promoters for MMP-1 and MMP-3 (sequences in A) and to
two known STAT3 recognition sequences (wild-type and mutant SIE m67
STAT binding site from the human c-fos promoter). Extracts were either
unstimulated or stimulated with IL-6 for 30 minutes as indicated before
complex formation was assessed by EMSA. The specificity of STAT3 DNA
binding was confirmed by supershifting using a STAT3-specific antibody.
Positions of STAT3-containing DNA–protein complexes are marked by
arrows. The asterisk (*) indicates background activity of unspecific DNA-
binding complexes.
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with STAT3. MMP-1A represents the sequence element
GAATTTCCGGGAAAAGG at position 4245 of the MMP-1
promoter, MMP-3A is the sequence element TTTCTTCCT-
GGAATTCA at position 1704 of the MMP-3 promoter.
Neither the second best (MMP-1B and MMP-3B) nor any
other putative STAT binding element from Figure 6B dis-
played significant complex formation with STAT3 in this
assay (results not shown).
We infer from these results that activated STAT3 immedi-
ately interacts with the human MMP-1 and MMP-3 promoter.
Discussion
There is accumulating evidence for the importance of onco-
genic signaling by STAT3 in the pathogenesis of various
human cancers. Thus, we focused on the contribution of
STAT3 to the onset and development of colorectal cancer.
Our previous work shows that STAT3 may contribute to
oncogenesis in the colon epithelium by exerting a promoting
effect on cell proliferation [5], whereas this paper demon-
strates its critical involvement in the enhancement of inva-
sive cell behavior.
One of the prerequisites for the invasiveness of tumor cells
is increased motility, and, of metastasis, a common feature
of late-stage CRC. The pleiotropic protein STAT3 is known to
exert control on cell motility in various settings. STAT3 is
crucial, e.g., for cell motility during gastrulation [48], wound
healing, and blood vessel formation [49]. We recently ob-
served that the invasiveness of trophoblast cells in pregnancy
is directly influenced through STAT3 activation [5,50].
More importantly, inadequate STAT3 activity was found
correlated with cancer-associated motility of breast [27,51]
and ovarian cancer [12] as well as of choriocarcinoma cells
[44]. In mesenchymal-like and colon carcinoma cells, STAT3
plays a critical role in the transmission of invasiveness-
promoting signaling by the c-Met receptor [52,53].
Altered invasiveness in transformed cells is a conse-
quence of changes in the status of cell adhesion, the cyto-
skeleton, and gene expression. STAT3 has been shown to act
on all these aspects: In addition to its well-established role as
a transcription factor, STAT3may also function as a signaling
adaptor at focal adhesions and, presumably, as a persistent
scaffold factor in cytokine/growth factor receptor assemblies
[12]. As recently reported, STAT3 can signal in an as yet
unknownway throughRhoGTPases, thus regulatingmultiple
cellular functions including actin cytoskeleton reorganization
and cell migration [54].
Transcriptional regulation of target genes provides an
obvious route through which STAT3 enhances cellular ma-
lignancy and, in particular, invasiveness. A central aspect of
invasiveness is the expression of proteases that render the
tumor cells capable of digesting constituents of the ECM.
Various reports point to a role of STAT3 in promoting invasive
cell behavior by exerting influence on the transcription of
protease genes. In metastatic melanoma cells, a link was
found between the expression of MMP-2, invasiveness, and
constitutive STAT3 activity. More importantly, inhibition of
STAT3 by a dominant-negative mutant reduced MMP-2 ex-
pression and invasiveness and blocked metastasis in nude
mice [55]. In skin epithelial cells, STAT3 was shown to
mediate the IL-6–provoked induction of MMP-1 and MMP-3
[56]. However, STAT3 is involved in controlling the expression
of MMP-7 in prostate carcinoma cells [26] and of MMP-9 in
cervix carcinoma cells [57].
We showed that STAT3 directly drives transcription from
the MMP-1 promoter in colon carcinoma cells and also
defined a binding site for STAT3 in the MMP-1 as well as in
the MMP-3 promoter. However, the precise role of STAT
factors in MMP gene regulation in colon cancer cells requires
further elucidation. Despite the presence of various additional
consensus sequences, we identified only one sequence
element in both the MMP-1 and the MMP-3 promoter that
specifically binds to activated STAT3. This finding leaves
open the possibility that the other elements interact with
STAT1 or STAT5, both of which are also frequently active in
CRC biopsies [5]. Furthermore, those sequences showing
no affinity for STAT3 in our assay may require additional
binding sites for the interaction with STAT3 tetramers, as re-
cently observed for other promoters [58,59].
Transcription of theMMP-1 gene is regulated in a complex
manner. The process appears to be influenced by the or-
chestrated action of various transcription factors and seems
also to depend on the type of cells involved. Apart from STAT
cognate elements, other regulatory elements within the
MMP-1 promoter region include various transcription factor
binding sites for AP-1, GATA binding, and ETS proteins
[60,61]. The cooperative contribution of AP-1 and ETS tran-
scription factors toward control of MMP-1 expression was
demonstrated by the observation that a single nucleotide
polymorphism creating an additional ETS binding site close
to the AP-1 recognition element at1602 bp results in greater
transcriptional activity [39]. However, we found that, starting
from different ‘‘basal’’ levels, STAT3 activation profoundly
enhanced transcription from both variants of the MMP-1
promoter in colon carcinoma cells (data not shown). The
relative importance of AP-1– and STAT-related signaling
pathways in the control of MMP-1 expression apparently
depends on the cell type. For instance, a specific inhibitor
of JAK3, a kinase operative in the activation of STATs, almost
completely inhibited MMP-1 mRNA induction and protein
abundance in human chondrocytes. In contrast, inhibition of
ERK1/2 kinases signaling via AP-1 had little effect on the
expression of MMP-1 in these cells [62]. We conclude that,
along with its importance in CRC proliferation and transfor-
mation, the STAT3 pathway is one driving force responsible
for overexpression and activity of MMP-1 in invasive colonic
cancer cells. The prognostic significance of MMP-1 expres-
sion in colorectal cancer has already been reported. High
levels of MMP-1 expression have been correlated with meta-
static spread of tumors and poor prognosis of colorectal
cancer [63–66]. Interestingly, MMP-1 inhibitors such as
batimastat blocked peritoneal carcinomatosis and liver me-
tastasis development in experimental colon carcinoma [67].
Of all the proteases addressed in study, MMP-1 is one
whose expression level is particularly linked with STAT3
activation in colorectal cancer. There are, however, other
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proteases whose expression level was also found to follow
the degree of STAT3 phosphorylation during the course of
this study. Induction of MMP-7 (matrilysin) expression in
prostate carcinoma cells by fibroblast growth factor was
shown to involve STAT3 through a probable interaction
with STAT binding sites within the matrilysin promoter [26].
A recent study reported a correlation between tyrosine-
phosphorylated STAT3 and expression of MMP-9 in breast
carcinoma cells and demonstrated a direct influence of
STAT3 on MMP-9 promoter activity [27].
The enzymatic activity of MMPs is specifically inhibited by
TIMPs, and high levels of TIMP-1 and TIMP-2 are associated
with aggressive cancers [62]. STAT3 has been described as
contributing to the downregulation of TIMP-1 expression in
synovial lining cells [22]. We recently found that STAT3
activation through leukemia inhibitory factor enhances inva-
siveness and coincides with a decrease of TIMP-1 expres-
sion in choriocarcinoma cells [44]. Interestingly, in the course
of this study we observed that TIMP-1 mRNA was signifi-
cantly less abundant in colorectal cancer biopsies with high
STAT3 activity (data not shown).
In conclusion, STAT3 activation can contribute to the
malignancy of many different types of cancer. One such con-
tribution involves the promotion of cell invasiveness through
(cell type specific) alteration in the pattern of protease activity.
Our data suggest that STAT3-controlled proteolysis via
MMPs is a major determinant of local tumor progression
andmetastasis of colorectal cancer and, thus, is an attractive
potential target for therapeutic intervention. Moreover, p-Y-
STAT3 andMMP-1 are likely to be of prognostic value or be of
diagnostic importance with regard to CRC progression.
Recent reports point to an important role of aberrant
STAT3 activity in metastasis of various malignant tumor
entities such as cutaneous squamous cell carcinoma [68],
melanoma [69], or hepatocellular carcinoma [70]. To investi-
gate the underlying molecular mechanisms, our future work
will include the analysis of patient CRC biopsy samples and
will take advantage of mouse models that closely mimic
stages of human CRC.
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